CG Oncology (CGON) Competitors

Grifols (NASDAQ:GRFS) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.

Which has more risk and volatility, GRFS or CGON?

Grifols has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500. Comparatively, CG Oncology has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500.

Is GRFS or CGON more profitable?

Grifols has a net margin of 0.00% compared to CG Oncology's net margin of -15,945.17%. Grifols' return on equity of 0.00% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	N/A	N/A	N/A
CG Oncology	-15,945.17%	-19.37%	-18.72%

Do insiders & institutionals believe in GRFS or CGON?

26.6% of CG Oncology shares are held by institutional investors. 0.2% of Grifols shares are held by insiders. Comparatively, 7.4% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Which has preferable earnings and valuation, GRFS or CGON?

Grifols has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$7.81B	0.94	$169.80M	$1.17	9.09
CG Oncology	$551K	3,665.72	-$88.04M	-$1.77	-14.97

Does the media favor GRFS or CGON?

In the previous week, CG Oncology had 8 more articles in the media than Grifols. MarketBeat recorded 14 mentions for CG Oncology and 6 mentions for Grifols. Grifols' average media sentiment score of 1.31 beat CG Oncology's score of 0.03 indicating that Grifols is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	1 Very Positive mention(s)	4 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate GRFS or CGON?

Grifols presently has a consensus price target of $10.30, indicating a potential downside of 3.20%. CG Oncology has a consensus price target of $55.30, indicating a potential upside of 108.76%. Given CG Oncology's stronger consensus rating and higher possible upside, analysts clearly believe CG Oncology is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	0 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.75
CG Oncology	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.08

Summary

CG Oncology beats Grifols on 9 of the 17 factors compared between the two stocks.